PAC1 (non-phospho), PACAP Receptor 1 Antibody

Figure 1. Validation of the PACAP Receptor 1 in transfected HEK293 cells. Native HEK293 cells (MOCK) or HEK293 cells stably expressing the human PACAP Receptor 1 (PAC1) were lysed and immunoblotted with the phosphorylation-independent anti-PAC1 antibody (7TM0370N-IC) at a dilution of 1:1000.

Figure 2. Immunocytochemical identification of PACAP Receptor 1 in HEK293 cells. HEK293 cells stably expressing the PACAP Receptor 1 (PAC1) were either not exposed or exposed to 1 μM PACAP (pituitary adenylate cyclase-activating peptide)) for 30 min and immunocytochemically stained with anti-PAC1 (PACAP Receptor 1) antibody (7TM0370N-IC) at a dilution of 1:200. Note, PAC1 receptors were confined to the plasma membrane in untreated cells (0 min). PAC1 receptors were seen in perinuclear clusters of vesicles after 30 min PACAP exposure.

Figure 3. Immunohistochemical identification of PACAP Receptor 1 in human enteric ganglia. Brain sections were dewaxed, microwaved in citric acid, and incubated with anti-PAC1 (PACAP Receptor 1) antibody (7TM0370N-IC) at a dilution of 1:100. Sections were then sequentially treated with biotinylated anti-rabbit IgG and avidin-biotin solution. Sections were then developed in 3,3-diaminobenzidine (DAB)-glucose oxidase and lightly counterstained with hematoxylin. Note, PAC1 receptors were uniformly detected in distinct population of cells in enteric ganglia.

Figure 4. Immunohistochemical identification of PACAP Receptor 1 in human neuroendocrine tumor. Brain sections were dewaxed, microwaved in citric acid, and incubated with anti-PAC1 (PACAP Receptor 1) antibody (7TM0370N-IC) at a dilution of 1:100. Sections were then sequentially treated with biotinylated anti-rabbit IgG and avidin-biotin solution. Sections were then developed in 3,3-diaminobenzidine (DAB)-glucose oxidase and lightly counterstained with hematoxylin. Note, PAC1 receptors were uniformly detected at the plasma membrane of nearly all cells in neuroendocrine tumor.

Figure 5. Immunohistochemical identification of PACAP Receptor 1 in human cerebral cortex. Brain sections were dewaxed, microwaved in citric acid, and incubated with anti-PAC1 (PACAP Receptor 1) antibody (7TM0370N-IC) at a dilution of 1:100. Sections were then sequentially treated with biotinylated anti-rabbit IgG and avidin-biotin solution. Sections were then developed in 3,3-diaminobenzidine (DAB)-glucose oxidase and lightly counterstained with hematoxylin. Note, PAC1 receptors were predominately detected at the plasma membrane of pyramidal cells in cerebral cortex.

Figure 6. Immunohistochemical identification of PACAP Receptor 1 in human ovarian carcinoma. Sections were dewaxed, microwaved in citric acid, and incubated with anti-PAC1 (PACAP Receptor 1) antibody (7TM0370N-IC) at a dilution of 1:100. Sections were then sequentially treated with biotinylated anti-rabbit IgG and avidin-biotin solution. Sections were then developed in 3,3-diaminobenzidine (DAB)-glucose oxidase and lightly counterstained with hematoxylin. Note, PAC1 receptors were uniformly detected at the plasma membrane of nearly all cells in ovarian carcinoma.

Figure 7. Immunohistochemical identification of PACAP Receptor 1 in human breast carcinoma. Sections were dewaxed, microwaved in citric acid, and incubated with anti-PAC1 (PACAP Receptor 1) antibody (7TM0370N-IC) at a dilution of 1:100. Sections were then sequentially treated with biotinylated anti-rabbit IgG and avidin-biotin solution. Sections were then developed in 3,3-diaminobenzidine (DAB)-glucose oxidase and lightly counterstained with hematoxylin. Note, PAC1 receptors were uniformly detected at the plasma membrane of nearly all breast carcinoma cells.